A new model to save lives and slow antimicrobial resistance
Aranda helps governments ensure the right antimicrobial is available in the right place at the right time – so patients get the treatment they need, and health systems can slow the spread of resistance.
Antimicrobial resistance is one of the world’s most urgent health threats. But the global response has focused largely on research and development, while the delivery problem remains unsolved.
In low- and middle-income countries, the failure is not one problem. It is a chain reaction:
- Stockouts of essential first-line antibiotics push clinicians toward second-line drugs
- Overuse accelerates resistance
- Resistance makes reserve medicines indispensable
- Reserve medicines remain out of reach because manufacturers have no commercial reason to register them in markets too small or unstable to recover their costs
The result is a system where patients die from infections that are treatable elsewhere, governments overspend on volatile procurement, and innovators struggle to generate sustainable returns from medicines the world urgently needs.
Aranda exists to break that cycle.
That model is Aranda.
We align governments, manufacturers, clinicians, and innovators around a fixed-price subscription model that gets the right drug to the right patient at the right time – while slowing resistance, reducing costs, and creating a viable market for antimicrobial innovation.
Our Edge
Aranda treats antimicrobial access as a coordination problem – not simply a supply problem, financing problem, or R&D problem.
Our model brings together disciplines that rarely operate as one: government delivery, pharmaceutical access, emerging-market execution, surveillance, stewardship, and commercial risk management.
That integration is what makes the model work. Aranda gives governments a single accountable system for antimicrobial access, with reliable supply, embedded stewardship, real-time surveillance, and fixed pricing.
For countries, this means predictable access and lower long-term cost.
For manufacturers, it means sustainable revenue in markets they cannot efficiently serve today.
For patients, it means the right medicine is there when it is needed.
Our Vision
A world where countries can treat antimicrobial access as core health infrastructure – planned, funded, and delivered reliably, without perpetual dependence on donors.
Aranda is designed for an ambitious but attainable goal: to slow antimicrobial resistance while saving lives today.
The model starts country by country, but the logic is global. When governments can access the full portfolio of antimicrobial medicines and diagnostics, use them appropriately, and fund them through a predictable, economically viable structure, the system begins to change.
Our Business Model
The Aranda subscription brings together everything a country needs to deliver antimicrobial access in one measurable, accountable, fixed-price package.
1. Medicines & Diagnostics
Reliable access to the full portfolio of antimicrobial medicines and diagnostic consumables – generic and on-patent – prescribed according to each country’s treatment guidelines.
2. Surveillance
Digitized infrastructure that integrates with existing government systems to track disease patterns, resistance trends, stock levels, prescribing behavior, and outcomes.
3. Stewardship
Continuous guideline review, clinician training, compliance monitoring, and an Aranda-funded delivery unit embedded inside the Ministry of Health.
4. Fixed Pricing
A single annual price over multiple years, with Aranda absorbing supply, pricing, and volume risk so governments can plan with confidence.
By expanding the subscription model beyond single reserve drugs to the full antimicrobial and diagnostics portfolio, Aranda creates the scale needed to generate procurement savings, fund surveillance and stewardship, and support country adoption through trade financing.
CONNECT WITH US
Aranda is building a commercially viable model to solve one of global health’s most urgent and intractable problems.